5Foley RN,Parfrey PS,Harnett JD,et al.Impact of hypertension on cardiomyopathy,morbidity and mortality in end-stage renal disease. Kidney International . 1996
3De Vries JPPM, Kouw PM, van der Meer NJM. Non-invasive monitoring of blood volume during hemodialysis: Its relation with post-dialytic dry weight. Kidney Int, 1993, 44: 851.
4Catherine C, Philippe M, Didier B. Lung, gastric, and soft tissue uptake of Tc-99m MDP and Ga-67 citrate associated with hypercalcemia. Clin Nucl Med, 2003, 28: 467-471.
5Argilés A, Mourad G. How do we have to use the calcium in the dialysate to optimize the management of secondary hyperparathyroidism? Nephrol Dial Transplant, 1998, 13 Suppl 3:62-64.
6Palmer, Biff F. Individualizing the dialysate in the hemodialysis patient. Semin Dial, 2001, 14: 41-49.
7Hou SH, Zhao J, Ellman CF, et al. Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis,1991, 2: 217-224.
8Argilés A, Kerr PG, Canaud B, et al. Hemodialysis and hemodiaffitration Ca kinetics, and the long-term effects of lowering dialysate calcium concentration. Kidney Int, 1993, 43: 630-640.
9Yudd M, Liach F. Renal osteodystrophy. In: Brenner BM, ed.Dialysis and transplantation. 北京: 科学出版社, 2001.14:259-260.
10Argilés A, Mion CM. Calcium balance and intact parathormone variations during haemodiafiltration. Nephrol Dial Transplant,1995, 10: 2083-2089.
7DeOreo P. Hemodialysis patient assessed functional health status predicts continued survival, hospitalization and dialysis- attendence compliance [ J ]. Am J Kidney Dis, 1997,30 (3) : 204-212.
8Mailloux L U, Levey A S. Hypertention in chronic renal disease [J]. Am j Kidney Dis, 1998(suppl 3), 32(1):S120- S141.
9Roy D J. Dignity dialysis and dying [J]. Dial Transplant, 1990, 19(1 ): 19-23.
10Farnier M. Combination therapy with and HMG-COA reductase inhibitor and a fibric acid derivative:a critical review of potential benefits and drawbacks[J].hm J Cardiovasc Drugs.2003.3(3):169-178.
